Katherine Li

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

P. Sonneveld, L. Pacaud, E. Zudaire, 2022, Blood.

First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.

H. Einsele, P. Moreau, J. San-Miguel, 2023, Journal of Clinical Oncology.

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

H. Einsele, A. Oriol, P. Moreau, 2023, The New England journal of medicine.